



ATTORNEY DOCKET NO. 9052-67

Patents

16938

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Colin Brown

Examiner: E. White

Serial No.: 09/700,057

Art Unit: 1623

Filed: February 5, 2001

For: *SURGICAL COMPOSITIONS AND METHODS FOR USING  
THE SAME*

COPY OF PAPERS  
ORIGINALLY FILED

August 20, 2002

RECEIVED

Commissioner for Patents  
Washington, D.C. 20231

AUG 29 2002

TECH CENTER 1600/2900

Sir:

Transmitted herewith is an AMENDMENT in the above-identified patent application.

☐ Applicant claims small entity status. See 37 CFR §1.27.

☐ No additional fee is required.

☒ Other:

The fee has been calculated as shown below:

(COL. 1)		(COL. 2)	(COL. 3)	SMALL ENTITY		OTHER THAN A SMALL ENTITY	
	Claims Remaining After Amendment	Highest Number Previously Paid For	Present Extra	RATE	ADDIT. FEE	OR RATE	ADDIT. FEE
Total	41 -	** 39	= 2	x 09=	\$	x 18=	\$ 36.00
Indep	3 -	*** 3	= 0	x 42=	\$	x 84=	\$
<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				+140=	\$	+280=	\$
				Total Add. Fee \$		OR Total	\$ 36.00

\* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

\*\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space. The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior Amendment or the number of claims originally filed.


MB

In re: Colin Brown  
Serial No.: 09/700,057  
Filed: February 5, 2001  
Page 2

---

- ☐ Please charge my Deposit Account No. 50-0220 in the amount of \$\_\_\_\_\_.
- ☒ A check in the amount \$36.00 to cover the additional fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-0220.
- ☒ Any additional filing fees required under 37 C.F.R. § 1.16 for the presentation of extra claims.
- ☒ Any patent application processing fees under 37 C.F.R. § 1.17.

Respectfully submitted,

  
Kenneth D. Sibley  
Registration No. 31,665  
Attorney of Record




20792

PATENT TRADEMARK OFFICE

#### CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on August 20, 2002.

  
Vickie Diane Prior

Date of Signature: August 20, 2002



*Replaced*

ATTORNEY DOCKET NO. 9052-67

Patents

#7/B  
RECEIVED 502  
AUG 29 2002  
*Done*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

In re: Colin Brown  
Serial No.: 09/700,057  
Filed: February 5, 2001  
For: **SURGICAL COMPOSITIONS AND METHODS FOR USING THE SAME**

Examiner: E. White  
Art Unit: 1623

August 20, 2002

**COPY OF PAPERS  
ORIGINALLY FILED**

Commissioner for Patents  
Washington, D.C. 20231

**AMENDMENT**

Sir:

This Amendment is responsive to the Office Action (the Action) mailed May 21, 2002. It is respectfully requested that this application be reconsidered in view of amendments and remarks set forth below. Attached hereto is a marked-up version of the changes made to the specification and the claims by the current amendment. The marked-up version of the changes is captioned "**Version With Markings To Show Changes Made.**"

**In the Specification:**

Please replace the paragraph at page 1, line 21 through page 2, line 3 with the following replacement paragraph:

*B*

-- WO 92/21354 describes a surgical adhesion as the attachment of organs or tissues to each other through scar tissue. A formation of scar tissue is described as a normal sequel to surgery or other tissue injury and is required for proper wound healing. In some cases, however, the scar tissue overgrows the intended region and creates surgical adhesions. These scar tissue surgical adhesions restrict the normal mobility and function of affected body parts. The invention disclosed in WP 92/21354 is based on the discovery that anionic polymers effectively inhibit invasion of cells associated with detrimental healing processes, ie, fibrosis, and scarring. In particular, certain inhibitory anionic polymers are useful to inhibit fibroblast invasion, thus